Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Target Price at $11.20

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average rating of “Buy” from the seven research firms that are covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $11.20.

A number of brokerages recently issued reports on IMUX. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Immunic in a report on Tuesday, July 16th. Leerink Partners reaffirmed an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Finally, Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th.

Immunic Stock Performance

Shares of IMUX opened at $1.40 on Friday. Immunic has a twelve month low of $0.95 and a twelve month high of $2.11. The firm’s fifty day simple moving average is $1.48 and its 200-day simple moving average is $1.34.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same period in the previous year, the company earned ($0.54) EPS. Sell-side analysts anticipate that Immunic will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. BVF Inc. IL acquired a new stake in shares of Immunic during the first quarter worth about $11,752,000. Janus Henderson Group PLC purchased a new stake in Immunic during the 1st quarter valued at approximately $9,266,000. Vanguard Group Inc. lifted its position in Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the period. Ikarian Capital LLC grew its stake in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the last quarter. Finally, Sierra Summit Advisors LLC purchased a new position in shares of Immunic in the 4th quarter valued at approximately $487,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.